Contact : +61 413 227 332

News & Articles

Livac New Staff Appointment

On 12th December 2016, Livac appointed Mr Richard Guise as its Product & Business Development Manager. Richard’s role will involve training distributor sales teams and supporting LiVac in the market. These activities are expected to grow distributor and end user (surgeon) confidence in the LiVac Retractor System and will underpin the achievement of company sales targets.

Read More

New Director Appointment

On 11th August 2016, four Livac Shareholders nominated Penelope Lane as a Non-Executive Director of Livac Holding Co. Pty Ltd, with the nomination accepted on the same day.

Read More

Livac Distributor Update

New Distributor Appointment & Commercial Order

On 31st October 2016, Livac Pty Ltd appointed Sistemas Integrales de Medicinia SA (Simmedica) as its exclusive distributor for the LiVac Retractor in Spain and Portugal.

Read More

FDA 510(k) Approval

It is with great pleasure that we announce the acceptance of the Livac 510(k) submission by the FDA.

The LiVac Retractor System was cleared by the US Food and Drug Administration (FDA) on 20th October 2016 with “no questions asked” and with the original acceptance notification received on 1st September, was approved within 2 months and in a much shorter time frame than originally expected.

Read More

Obesity Surgery, October 2016

One-Anastomosis Jejunal Interposition with Gastric Remnant Resection (Branco-Zorron Switch) for Severe Recurrent Hyperinsulinemic Hypoglycemia after Gastric Bypass for Morbid Obesity

Zorron, R., Branco, A., Sampaio, J. et al. OBES SURG (2016). doi:10.1007/s11695-016-2410-y



The anatomical and physiological changes after Roux-en-Y gastric bypass for morbid obesity can lead to severe hyperinsulinemic hypoglycemia with neuroglycopenia in a small percentage of patients. The exact physiologic mechanism is not completely understood. Surgical reversal to the original anatomy and distal or total pancreatectomy are current therapeutic options to reverse the hypoglycemic effect, with substantial associated morbidity. Our group reports a pilot clinical series of a novel surgical technique using one-anastomosis jejunal interposition with gastric remnant resection (Branco-Zorron Switch).

Read More